// App-Quantinova.ai

1528 : Resolution of Enthesitis and Dactylitis Is Maintained over Two Years of Ixekizumab Treatment in Patients with Psoriatic Arthritis

Researchers

Presenter

  • Lihi Eder

Principal Investigators

  • Josef Smolen

  • Matthew M. Hufford

  • Chen-Yen Lin

  • Aubrey Trevelin Sprabery

  • Dennis McGonagle

Medical Centers

  • University of California, San Diego School of Medicine, La Jolla, CA

  • Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada

  • Medical University of Vienna, Vienna, Austria

  • Eli Lilly and Company, Indianapolis, IN

  • University of Leeds, Leeds, United Kingdom

Locations

  • United States

  • Canada

  • Austria

  • United Kingdom

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved